DIA Annual Canadian Meeting

Transformation with Collaboration

Back to Agenda

Session 6: Track C: Best Practices in Policy Development and Direction

Session Chair(s)

Lissa Murseli

Manager

Health Canada, Canada

This session will give an overview of relevant policy areas in Canada, such as cannabis and/or opioids. Speakers will highlight key policy areas that are underway or emerging. The session will describe some lessons learned or best practices in these policy areas, including engagement of relevant players in the policy development process.

Learning Objective : At the conclusion of this session, participants should be able to:
Explain the Canadian context of key policy issues in Canadian healthcare product policy
Describe existing and emerging healthcare product areas in Canada
Discuss the policy development process and best practices for stakeholder engagement

Speaker(s)

Citizen-Focused Drug Policy Development: Working with (and for) People with Lived and Living Experience with Drug Use

Ian Hodges

Health Canada, Canada

Manager, Policy Development, Office of Drug Policy and Science

Proactive Monitoring: A New Approach to Health Canada’s Oversight of Health Products Advertising

Alain G. Musende, PhD

Marketed Health Products Directorate, Health Canada, Canada

Manager, Section for Transparency and Advertising Regulatory Surveillance

A Discussion of Innovation and Collaboration Frameworks for Medical Cannabis

Setu Purohit, JD

Avicanna Inc., Canada

Co-Founder, President, Chief Legal Officer

Have an account?